Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) FCF Margin: 2009-2025

Historic FCF Margin for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to 8.92%.

  • Lifecore Biomedical's FCF Margin fell 693.00% to 8.92% in Q2 2025 from the same period last year, while for May 2025 it was -10.57%, marking a year-over-year increase of 357.00%. This contributed to the annual value of -10.57% for FY2025, which is 357.00% up from last year.
  • Latest data reveals that Lifecore Biomedical reported FCF Margin of 8.92% as of Q2 2025, which was up 173.66% from -12.11% recorded in Q1 2025.
  • Lifecore Biomedical's FCF Margin's 5-year high stood at 15.84% during Q2 2024, with a 5-year trough of -70.94% in Q1 2023.
  • Moreover, its 3-year median value for FCF Margin was -19.07% (2024), whereas its average is -21.75%.
  • In the last 5 years, Lifecore Biomedical's FCF Margin slumped by 8,639bps in 2021 and then soared by 4,914bps in 2024.
  • Lifecore Biomedical's FCF Margin (Quarterly) stood at -39.98% in 2021, then spiked by 1,161bps to -28.36% in 2022, then skyrocketed by 1,850bps to -9.86% in 2023, then tumbled by 1,649bps to -26.35% in 2024, then slumped by 693bps to 8.92% in 2025.
  • Its FCF Margin was 8.92% in Q2 2025, compared to -12.11% in Q1 2025 and -26.35% in Q4 2024.